LBT-3627

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP), designed to modulate immune cell behavior in neurodegenerative diseases, particularly Parkinson's disease. It acts as a selective agonist of the vasoactive intestinal peptide receptor 2 (VPAC2), shifting immune responses from neurotoxic to neuroprotective and promoting the survival of dopamine-producing neurons. Unlike native VIP, which is rapidly degraded and non-selective between VPAC1 and VPAC2 receptors, LBT-3627 demonstrates greater biological stability and selectivity for VPAC2. Preclinical studies have shown that it can reduce inflammatory microglia activity, increase regulatory T cell function, protect dopaminergic neurons, and potentially halt or slow disease progression by rebalancing immune responses. The drug is being developed primarily for Parkinson’s disease but has also received funding for evaluation in amyotrophic lateral sclerosis (ALS). Development is led by Longevity Biotech in collaboration with academic partners such as the University of Nebraska Medical Center[1][3][4][5][6][8].